SynthesisFrontiers in endocrinology2025
Immune checkpoint inhibitors-induced thyroid dysfunction improves the prognosis of patients with lung cancer: a meta-analysis and systematic review.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- The role of hormonal and nutritional biomarkers in predicting immune checkpoint inhibitor efficacy: current limitations and future prospects.Frontiers in immunology · 2026Review
- Immune checkpoint inhibitor-related thyroid dysfunction during treatment of lung cancer: a disproportionality analysis based on the FDA adverse event reporting system.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Several studies have explored the impact of immune checkpoint inhibitor (ICI)-induced immune-related thyroid dysfunction on the prognosis of patients with lung cancer. However, inconsistencies remain among the results of different studies. Therefore, we conducted a meta-analysis to evaluate the impact of immune-related thyroid dysfunction on the prognosis of lung cancer, aiming to provide evidence-based support for clinical treatment. Methods: We searched PubMed, Embase, the China National Knowledge Infrastructure (CNKI), and the Cochrane Library to identify studies on the association between immune-related thyroid dysfunction and the prognosis of patients with lung cancer. The search period spanned from the establishment of each database to November 2025. Two researchers independently performed literature screening, data extraction, and assessment of the risk of bias in the included studies. A meta-analysis was performed using RevMan 5.3 software. Results: A total of 14 studies involving 2,252 patients with lung cancer were included. The meta-analysis showed that ICI-induced immune-related thyroid dysfunction improved the overall survival (OS) (HR = 0.47, 95% confidence interval, CI [0.39, 0.56], Conclusions: In patients with lung cancer receiving immunotherapy, the development of thyroid dysfunction (a treatment-related adverse event) may indicate a more robust immune response to the therapy, which is associated with improved treatment outcomes. This finding provides evidence-based support for predicting the prognosis of patients with lung cancer treated with ICIs. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251267541.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.